ALNT · Allient Inc. · Stock research

Current Thesis

The fundamental leg is unchanged from the 2026-08-05 report: orders of $201.3M (+49% YoY), a 1.31x book-to-bill, backlog of $298.0M against $236.6M a year earlier, and a record 34.9% gross margin. What has changed in the week since is the identity of the seller. A Form 4 filed 2026-08-12 shows CEO Richard S. A day later, a Schedule 13D/A dated 2026-08-13 disclosed that Juniper Targeted Opportunity Fund sold 165,991 shares between 2026-08-11 and 2026-08-13 for approximately $18,792,719 aggregate, leaving the Juniper reporting persons at 596,314 shares, about 3.5% of outstanding. The order inflection and the distribution are both real and both dated.

Bullish and bearish views on Allient Inc.

The model's bull view on Allient Inc. (ALNT), in brief: Orders $201.3M in Q2 2026, +49% YoY; book-to-bill 1.31x; backlog $298.0M vs $236.6M at Q2 2025 quarter end (Q2 2026 results release, 2026-08-05). The bear view: The largest insider and a 13D holder both sold into the high. Both cases follow in full.

Bull Case

• Orders $201.3M in Q2 2026, +49% YoY; book-to-bill 1.31x; backlog $298.0M vs $236.6M at Q2 2025 quarter end (Q2 2026 results release, 2026-08-05). The order break follows two flat revenue years.
• Revenue $153.770M vs $145.685M consensus; adjusted EPS $0.80 vs $0.61 consensus (Benzinga recap, 2026-08-05). GAAP net income $10.4M / $0.61 diluted, +85% YoY; adjusted EBITDA $23.7M, 15.4% of revenue.
• Gross margin 34.9%, +170bp YoY, called a record in the release and attributed to volume, mix and internal efficiency work. Operating margin 10.2%.
• JP Morgan raised its target twice in 25 days — to $95 from $80 on 2026-07-13, then to $120 from $95 on 2026-08-07, maintaining Overweight. Estimate revisions are still moving up, not down.
• Balance sheet leaves room: cash $42.1M, total debt $173.3M, leverage 1.63x at Q2 2026 quarter end, with management having flagged acquisition monitoring after deleveraging.
• The dividend was stepped up to $0.04 per share (record 2026-08-19) from the $0.03 paid 2026-04-03.

Bear Case

• The largest insider and a 13D holder both sold into the high. CEO trust sales at $112.49–$115.765 on 2026-08-10 (Form 4, 2026-08-12) and 165,991 Juniper shares for ~$18,792,719 through 2026-08-13 (13D/A) landed within pennies of the $114.28 52-week high. Ownership remains large — but the marginal supply now has a name.
• Cash conversion is negative. Free cash flow was -$18.31M in Q2 2026 versus +$22.38M in Q2 2025, on higher receivables and inventory. The order build is financed through working capital.
• One quarter proves nothing about a cycle. A single 1.31x book-to-bill against a two-year flat revenue base is a data point; the $298.0M backlog has yet to convert.
• Rare-earth exposure is disclosed and unresolved. On the Q2 2025 call management said $3–4M of revenue was pulled forward on customer concern about heavy rare earth constraints.
• Restructuring costs tied to the Dothan transition are still running through the P&L (Q2 2026 release).
• Sell-side coverage is thin and stale. Aggregator summaries dated 2026-08-12 show six covering analysts, four buy / two hold, with trailing average targets in the $76–$84 range — most have not refreshed since the print, so the $120 from JP Morgan is close to the only published number above spot.

Setup & Price Structure

The narrative is maturing. Dating it: the headline flow stopped on 2026-08-07 (JP Morgan's $120), the 52-week high of $114.28 was set in the following sessions, and the two filings that hit the tape afterwards — the 2026-08-12 Form 4 and the 2026-08-13 13D/A — were supply, not new narrative. The last completed daily close, 2026-08-14, was $111.41, 2.5% under that high, with RSI(14) at 73.7 against 75.5 on 2026-08-07. The story is well known and still working; the incremental bid is no longer arriving with fresh headlines. That band is the origin of the move. The three-month return is 81.8%. Since 2026-08-07 the price has held a narrow range beneath $114.28 without giving back the gap, which is a consolidation too short to call a shelf.

Crowding and positioning observables, stated as observables: RSI 73.7 after an 81.8% three-month advance; price within 2.5% of an all-time-area high; a 13D holder reduced to ~3.5%; no company-dated event between the 2026-09-02 dividend payment and the Q3 print expected in early November.

Catalyst Calendar (next 30 days)

• 2026-09-02 — Dividend payment date. Cash leaves the balance sheet in a quarter that followed -$18.31M free cash flow.
• Ongoing, any date — Further Form 4 or 13D/A amendments. Juniper's stake is now ~3.5%; additional sales, or a stop, are filed and visible within two business days.
• ~2026-11-04 (est.), outside the 30-day window — Q3 2026 results and call. Q2 cadence was release 2026-08-05, call 2026-08-06. This is the first genuine test of the thesis and nothing before it is comparable in weight.

Elapsed catalysts

• 2026-08-19 — Record date, $0.04 quarterly dividend. Confirms the step-up from $0.03; a capital-allocation marker, it resolves nothing about backlog conversion. (passed 7d ago)

What Would Change Our Mind

The structural break is the post-print gap. Shares moved from a $93.25 grant reference on 2026-08-05 to $114.28 in four sessions; that move is what the record-orders quarter bought, and losing it undoes the argument. A weekly close below $96 round-trips it entirely, with the $96.02 first print on the 2026-08-05 report as the reference. Ahead of that, a daily close that fails to hold the low $100s would mark the first crack in an otherwise untested consolidation.

On fundamentals, the thesis breaks if the Q3 2026 release shows book-to-bill under 1.0x or backlog below $298.0M — either would recast the 49% order jump as pull-forward. A second consecutive quarter of negative free cash flow with leverage rising from 1.63x would break the deleveraging leg independently of price. Conversely, a Q3 book-to-bill again above 1.0x with backlog above $298.0M and free cash flow back positive would re-date the narrative as accelerating rather than maturing.

Correlation Notes

• Revenue is spread across industrial automation, vehicle, medical and aerospace/defense end markets, so the order book tracks small-cap industrial capex rather than any single secular theme; the name trades with the small-cap industrial complex and the Russell 2000, not with semis.
• Permanent-magnet motors tie the input cost line to heavy rare earth availability — the same constraint management quantified as a $3–4M revenue pull-forward on the Q2 2025 call. Chinese export-control headlines move the whole motion-control group together.
• The company reports organic constant-currency growth separately from reported growth, so euro and other non-dollar translation is a visible swing factor between the two lines.